Breaking Finance News

NewLink Genetics (NYSE:NLNK) target bumped up to $22.00, released a research note earlier today by Bank of America (Merrill Lynch)

Bank of America (Merrill Lynch) bumped up the price target of NewLink Genetics (NYSE:NLNK) to $22.00 reporting a potential upside of 1.01%.

Previously on 9/11/2017, Stifel Nicolaus reported on NewLink Genetics (NYSE:NLNK) increased the target price from $14.00 to $29.00. At the time, this indicated a possible upside of 0.69%.

Yesterday NewLink Genetics (NYSE:NLNK) traded 1.16% higher at $10.94. The company’s 50-day moving average is $10.67 and its 200-day moving average is $11.52. The last closing price is down -1.24% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 1,695,102 shares of the stock traded hands, down from an average trading volume of 2,542,700

See Chart Below

NewLink Genetics (NYSE:NLNK)

NewLink Genetics has a 52 week low of $5.90 and a 52 week high of $25.17 The company’s market cap is currently $0.

In addition to Bank of America (Merrill Lynch) reporting its target price, a total of 6 firms have reported on NewLink Genetics. The 12-month price target is $34.33 with two analysts rating the company a strong buy, three equity analysts rating the company a buy, one brokerage rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About NewLink Genetics (NYSE:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.